Display Settings:

Format

Send to:

Choose Destination
    Curr Pharm Des. 2007;13(24):2485-92.

    Overcoming chondroitin sulphate proteoglycan inhibition of axon growth in the injured brain: lessons from chondroitinase ABC.

    Source

    Cellular and Molecular Basis of Neurodegeneration and Neurorepair, Department of Cell Biology and Institute for Research in Biomedicine, Parc Científic de Barcelona, Universitat de Barcelona, Spain. jadelrio@pcb.ub.es

    Abstract

    The presence of numerous axon-inhibitory molecules limits the capacity of injured neurons in the adult mammalian central nervous system (CNS) to regenerate damaged axons. Among others, chondroitin sulphate proteoglycans (CSPGs) enriched in glycosaminoglycan (GAG) chains, acting intracellularly via Rho GTPase activation and cytoskeletal modification, prevent axon re-growth after injury. However, axon regeneration can be induced by modulating the extrinsic environment or the intrinsic neural response to axon extension. Among other strategies, the use of chondroitinase ABC (ChABC) to degrade GAGs and decrease CSPG-associated inhibition has been analyzed. Recent reports have extended the use of this enzyme, in combination with cell transplantation or pharmacological treatment. The steady advances made in these combinations offer promising perspectives for the development of new therapies to repair the injured nervous system.

    PMID:
    17692016
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Bentham Science Publishers Ltd.

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk